The efficacy of SRPK, CLK and CDK inhibitors has now been tested in multiple preclinical studies and hold promise that these drugs can represent valuable anti‐neoplastic agents, especially for cancer types that are driven by transcriptional and co‐transcriptional dysregulation of gene expression programmes [162]. The gene discussed is CLK1; the disease is cancer.